Modulation of tumor immunity
Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
1. A method of treating a tumor in a patient comprising administering to the patient a PD-1 antagonist and a GITR agonist, wherein the PD-1 antagonist is MK-3475 or antigen binding fragment thereof; wherein the GITR agonist is an antibody or antigen binding fragment thereof that comprises a light chain variable region that comprises CDR-L1, CDR-L2 and CDR-L3 of a light chain variable region of SEQ ID NO: 82 and a heavy chain variable region that comprises CDR-H1, CDR-H2 and CDR-H3 of a heavy chain variable region of SEQ ID NO:81; wherein CDR-L1 comprises amino acids 24-38 of SEQ ID NO:82 and amino acid 31 is N or Q, CDR-L2 comprises amino acids 54-60 of SEQ ID NO:82 and amino acid 57 is N or Q, CDR-L3 comprises amino acids 93-101 of SEQ ID NO:82, CDR-H1 comprises amino acids 26-35 of SEQ ID NO:81, CDR-H2 comprises amino acids 50-65 of SEQ ID NO:81, and CDR-H3 comprises amino acids 98-107 of SEQ ID NO:81; and wherein the PD-1 antagonist and GITR agonist are administered simultaneously or sequentially.
2. The method of claim 1 , wherein the PD-1 antagonist and GITR agonist are administered simultaneously at least one time.
3. The method of claim 1 , wherein the PD-1 antagonist and GITR agonist are administered simultaneously at least 2 times.
4. The method of claim 1 , wherein the tumor is an advanced stage tumor.
5. The method of claim 4 , wherein the advanced stage tumor is selected from the group consisting of squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, glioma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, myeloma, multiple myeloma, salivary gland carcinoma, kidney cancer, renal cell carcinoma, Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, and esophageal cancer.
6. The method of claim 1 , wherein the GITR agonist is an antibody having:
a) a heavy chain variable region of SEQ ID NO: 81; and
b) a light chain variable region of SEQ ID NO: 82, wherein amino acid 31 of SEQ ID NO: 82 is Q and amino acid 57 of SEQ ID NO: 82 is Q.
7. The method of claim 1 , wherein the GITR agonist is an antibody or antigen binding fragment thereof that comprises a light chain variable region that comprises CDR-L1 of SEQ ID NO:34, CDR-L2 of SEQ ID NO:45, and CDR-L3 of SEQ ID NO:56; and a heavy chain variable region that comprises CDR-H1 of SEQ ID NO:1, CDR-H2 of SEQ ID NO:12, and CDR-H3 of SEQ ID NO:23.